Cite
Usmani SZ, Karanes C, Bensinger WI, et al. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021;35(12):3526-3533doi: 10.1038/s41375-021-01262-w.
Usmani, S. Z., Karanes, C., Bensinger, W. I., D'Souza, A., Raje, N., Tuchman, S. A., Sborov, D., Laubach, J. P., Bianchi, G., Kanagavel, D., Saleem, R., Dubin, F., Campana, F., & Richardson, P. G. (2021). Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia, 35(12), 3526-3533. https://doi.org/10.1038/s41375-021-01262-w
Usmani, Saad Z, et al. "Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma." Leukemia vol. 35,12 (2021): 3526-3533. doi: https://doi.org/10.1038/s41375-021-01262-w
Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 Dec;35(12):3526-3533. doi: 10.1038/s41375-021-01262-w. Epub 2021 May 28. PMID: 34050260; PMCID: PMC8632673.
Copy
Download .nbib